Canaccord Genuity reiterated their buy rating on shares of Sientra, Inc. (NASDAQ:SIEN) in a research report released on Sunday morning. They currently have a $14.00 price target on the medical instruments supplier’s stock.
SIEN has been the subject of a number of other research reports. Lake Street Capital reiterated a buy rating and issued a $15.00 target price (up previously from $11.00) on shares of Sientra in a research report on Wednesday, August 2nd. Stifel Nicolaus reiterated a hold rating and issued a $14.00 target price (up previously from $11.00) on shares of Sientra in a research report on Wednesday, September 27th. William Blair upgraded shares of Sientra from a market perform rating to an outperform rating in a research report on Wednesday, September 13th. Stephens began coverage on shares of Sientra in a research report on Tuesday, July 11th. They issued an overweight rating and a $12.00 target price for the company. Finally, ValuEngine upgraded shares of Sientra from a sell rating to a hold rating in a research report on Thursday, June 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $13.75.
Shares of Sientra (NASDAQ:SIEN) opened at 15.88 on Friday. The stock’s 50 day moving average is $13.71 and its 200 day moving average is $10.20. The stock’s market capitalization is $306.58 million. Sientra has a 52 week low of $6.92 and a 52 week high of $16.49.
Sientra (NASDAQ:SIEN) last released its earnings results on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.04. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. The company had revenue of $8.20 million during the quarter, compared to the consensus estimate of $6.97 million. The company’s revenue was up 32.3% on a year-over-year basis. Analysts anticipate that Sientra will post ($2.94) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Sientra’s (SIEN) “Buy” Rating Reiterated at Canaccord Genuity” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/10/11/sientras-sien-buy-rating-reiterated-at-canaccord-genuity.html.
Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. acquired a new position in shares of Sientra during the 2nd quarter worth $101,000. Nationwide Fund Advisors increased its stake in shares of Sientra by 260.4% during the 2nd quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 7,921 shares during the last quarter. Accredited Investors Inc. acquired a new position in shares of Sientra during the 2nd quarter worth $115,000. Wells Fargo & Company MN increased its stake in shares of Sientra by 0.3% during the 1st quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 40 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Sientra during the 1st quarter worth $117,000. Institutional investors own 77.61% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
What are top analysts saying about Sientra Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sientra Inc. and related companies.